Jazz Pharmaceuticals PLC
(HAM:J7Z)
€
209.5
+9.8 (+4.91%)
Market Cap: 13.30 Bil
Enterprise Value: 15.53 Bil
PE Ratio: 0
PB Ratio: 3.45
GF Score: 73/100 Jazz Pharmaceuticals PLC at Bank of America Healthcare Conference Transcript
May 10, 2022 / 07:40PM GMT
Jason Matthew Gerberry
BofA Securities, Research Division - MD in US Equity Research
All right, everybody. Thanks for joining us for today's afternoon session of the Bank of America Annual Healthcare Conference. My name is Jason Gerberry, I cover biotech and spec pharma. Pleased to be introducing our next company presenter, Jazz Pharmaceuticals. We've got CEO, Bruce Cozadd; Dan Swisher, President; and Philip Jochelson who is the Therapeutic Head of CNS. So Bruce has like a couple of minutes of prepared remarks, and then we'll jump into Q&A.
Bruce C. Cozadd
Jazz Pharmaceuticals plc - Co-Founder, Chairman & CEO
So how long is our session, if I talk for the whole session, then no Q&A, right?
Jason Matthew Gerberry
BofA Securities, Research Division - MD in US Equity Research
My clock is running at 27.
Bruce C. Cozadd
Jazz Pharmaceuticals plc - Co-Founder, Chairman & CEO
So Jason, it's great to be here. It's great to see people in person, it's just been
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot